Boehringer Ingelheim Reports 'Groundbreaking' Results With Survodutide in Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Survodutide, a GLP-1 receptor dual agonist with a novel mechanism of action, was the first treatment to produce findings this significant in a Phase II trial of metabolic dysfunction-associated steatohepatitis.

Source link
#Boehringer #Ingelheim #Reports #039Groundbreaking039 #Results #Survodutide #Treatment #Metabolic #DysfunctionAssociated #Steatohepatitis